GSK stock news
Every headline mentioning GSK from Investing.com, BioPharma Dive and Nasdaq over the last 30 days, each scored for sentiment and importance. Updated automatically through the trading day.
Latest GSK headlines
Tuesday, 17 November 2026
Friday, 30 October 2026
Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game
Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood a tumultuous quarter and GSK battled investor angst.
Wednesday, 28 October 2026
Tuesday, 27 October 2026
Monday, 26 October 2026
Ris-Rez Reduced Risk of Disease Progression or Death by 67% Versus Chemotherapy in Patients with Relapsed Osteosarcoma in China
BlackRock ETF Trust II - iShares Flexible Income Active ETF's filing packet contains an announcement from GSK plc regarding positive results from its ARTEMIS-011 study. The pivotal phase III trial in China evaluated risvutatug…
GSK cancer drug clears rectal tumours in 76% of patients in trial, data shows
Wednesday, 21 October 2026
GSK, Ionis win US approval for first-of-its-kind hepatitis B drug
Hibsago is viewed as a potential “functional cure” for chronic infections and an important part of the British drugmaker’s goal of reaching £40 billion in annual revenue by 2031.